These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 33031368)

  • 1. Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers During the COVID-19 Pandemic: A Modeling Analysis.
    Sadria M; Layton AT
    PLoS Comput Biol; 2020 Oct; 16(10):e1008235. PubMed ID: 33031368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
    Rico-Mesa JS; White A; Anderson AS
    Curr Cardiol Rep; 2020 Apr; 22(5):31. PubMed ID: 32291526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin-angiotensin-aldosterone system and COVID-19 infection.
    Alexandre J; Cracowski JL; Richard V; Bouhanick B;
    Ann Endocrinol (Paris); 2020 Jun; 81(2-3):63-67. PubMed ID: 32370986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
    Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
    Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust.
    Bean DM; Kraljevic Z; Searle T; Bendayan R; Kevin O; Pickles A; Folarin A; Roguski L; Noor K; Shek A; Zakeri R; Shah AM; Teo JTH; Dobson RJB
    Eur J Heart Fail; 2020 Jun; 22(6):967-974. PubMed ID: 32485082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies.
    Albini A; Di Guardo G; Noonan DM; Lombardo M
    Intern Emerg Med; 2020 Aug; 15(5):759-766. PubMed ID: 32430651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.
    Xu J; Huang C; Fan G; Liu Z; Shang L; Zhou F; Wang Y; Yu J; Yang L; Xie K; Huang Z; Huang L; Gu X; Li H; Zhang Y; Wang Y; Hayden FG; Horby PW; Cao B; Wang C
    Front Med; 2020 Oct; 14(5):601-612. PubMed ID: 32621202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy.
    Chung MK; Karnik S; Saef J; Bergmann C; Barnard J; Lederman MM; Tilton J; Cheng F; Harding CV; Young JB; Mehta N; Cameron SJ; McCrae KR; Schmaier AH; Smith JD; Kalra A; Gebreselassie SK; Thomas G; Hawkins ES; Svensson LG
    EBioMedicine; 2020 Aug; 58():102907. PubMed ID: 32771682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19.
    Kai H; Kai M
    Hypertens Res; 2020 Jul; 43(7):648-654. PubMed ID: 32341442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
    Cadegiani FA; Goren A; Wambier CG
    Med Hypotheses; 2020 Oct; 143():110112. PubMed ID: 32721806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
    Huang Y; Xie C; Chen X; Hong Q; Huang H
    Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834
    [No Abstract]   [Full Text] [Related]  

  • 12. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
    Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L
    JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients.
    Baral R; White M; Vassiliou VS
    Curr Atheroscler Rep; 2020 Aug; 22(10):61. PubMed ID: 32830286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
    Sarzani R; Giulietti F; Di Pentima C; Giordano P; Spannella F
    Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L325-L336. PubMed ID: 32639866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).
    Mehta N; Kalra A; Nowacki AS; Anjewierden S; Han Z; Bhat P; Carmona-Rubio AE; Jacob M; Procop GW; Harrington S; Milinovich A; Svensson LG; Jehi L; Young JB; Chung MK
    JAMA Cardiol; 2020 Sep; 5(9):1020-1026. PubMed ID: 32936273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Renin-Angiotensin-Aldosterone System in Coronavirus Infection-Current Considerations During the Pandemic.
    Augoustides JGT
    J Cardiothorac Vasc Anesth; 2020 Jul; 34(7):1717-1719. PubMed ID: 32360010
    [No Abstract]   [Full Text] [Related]  

  • 17. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.
    Danser AHJ; Epstein M; Batlle D
    Hypertension; 2020 Jun; 75(6):1382-1385. PubMed ID: 32208987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
    Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
    Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome.
    Lam KW; Chow KW; Vo J; Hou W; Li H; Richman PS; Mallipattu SK; Skopicki HA; Singer AJ; Duong TQ
    J Infect Dis; 2020 Sep; 222(8):1256-1264. PubMed ID: 32702098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of ACEi and ARB in COVID-19 management: A retrospective analysis.
    Kumar S; Nikravesh M; Chukwuemeka U; Randazzo M; Flores P; Choday P; Raja A; Aseri M; Shivang S; Chaudhuri S; Barve P
    Clin Cardiol; 2022 Jul; 45(7):759-766. PubMed ID: 35481554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.